نتایج جستجو برای: myelofibrosis
تعداد نتایج: 4073 فیلتر نتایج به سال:
Myelofibrosis is reported in patents with primary hyperparathyroidism. It is also was reported in patents with sec- ondary hyperparathyroidism due to end-stage renal disease or Vitamin D dependent rickets .We present a case of celiac disease and osteomalacia which leads to secondary hyperparathyroidism and myelofibrosis.
myelofibrosis is reported in patents with primary hyperparathyroidism. it is also was reported in patents with sec- ondary hyperparathyroidism due to end-stage renal disease or vitamin d dependent rickets .we present a case of celiac disease and osteomalacia which leads to secondary hyperparathyroidism and myelofibrosis.
Bone marrow fibrosis leading to dry tap aspiration and often associated with blast crisis has previously been reported in both Chronic myeloid leukemia Primary myelofibrosis. The similarities between these two conditions terms of clinical presentation morphology can really create a diagnostic dilemma. Here we present case 32 year old lady which closely resembled myelofibrosis transformation. Al...
555 Abstract: The importance of bone marrow biopsy in Hodgkin’s disease is well known. The incidence of bone marrow involvement in Hodgkin’s disease varies from 2% to 29%. The presence of myelofibrosis is not sufficent evidence for a definitive diagnosis of bone marrow involvement. Patients having myelofibrosis as a first symptom without peripheral lympadenopathy must be distinguished from pati...
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and diarrhea) and constitutional symptoms, represent a substantial burden to patients. Most patients eventually die from the disease, with a median su...
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility. In a comparison of three recent classifications, overall concordance was 79%. Inclusion of raised serum lactate dehydrogenase categorized 9% ...
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE). In addition, myelofibrosis presenting as cytopenias and showing clinical response to immunosuppressant drugs, notably steroids, has been reported ...
OBJECTIVE To date, only a small number of epidemiological studies on myelofibrosis have been performed. The current study aimed to characterize the myelofibrosis patient population in Belgium according to pre-defined disease parameters (diagnosis, risk categories, hemoglobin <10 g/dl, spleen size, constitutional symptoms, platelet count, myeloblast count), with a view to obtaining a deeper unde...
BACKGROUND The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under question, and there has been interest in identifying additional mutations that may contribute to disease pathogenesis. Because ASXL1 lesions ha...
On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. This approval was based on the...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید